Summary
There is a need to validate risk assessment tools for hospitalised medical patients
at risk of venous thromboembolism (VTE). We investigated whether a predefined cut-off
of the Geneva Risk Score, as compared to the Padua Prediction Score, accurately distinguishes
low-risk from high-risk patients regardless of the use of thromboprophylaxis. In the
multicentre, prospective Explicit ASsessment of Thromboembolic RIsk and Prophylaxis
for Medical PATients in SwitzErland (ESTIMATE) cohort study, 1,478 hospitalised medical
patients were enrolled of whom 637 (43%) did not receive thromboprophylaxis. The primary
endpoint was symptomatic VTE or VTE-related death at 90 days. The study is registered
at ClinicalTrials.gov, number NCT01277536. According to the Geneva Risk Score, the
cumulative rate of the primary endpoint was 3.2% (95% confidence interval [CI] 2.2–4.6%)
in 962 high-risk vs 0.6% (95% CI 0.2–1.9%) in 516 low-risk patients (p=0.002); among
patients without prophylaxis, this rate was 3.5% vs 0.8% (p=0.029), respectively.
In comparison, the Padua Prediction Score yielded a cumulative rate of the primary
endpoint of 3.5% (95% CI 2.3–5.3%) in 714 high-risk vs 1.1% (95% CI 0.6–2.3%) in 764
lowrisk patients (p=0.002); among patients without prophylaxis, this rate was 3.2%
vs 1.5% (p=0.130), respectively. Negative likelihood ratio was 0.28 (95% CI 0.10–0.83)
for the Geneva Risk Score and 0.51 (95% CI 0.28–0.93) for the Padua Prediction Score.
In conclusion, among hospitalised medical patients, the Geneva Risk Score predicted
VTE and VTE-related mortality and compared favourably with the Padua Prediction Score,
particularly for its accuracy to identify low-risk patients who do not require thromboprophylaxis.
Keywords
Venous thromboembolism - internal medicine - risk assessment - thromboprophylaxis
- validation studies